Rheumatology tests top the list of FDA-approved biomarker panels today. But the most prominent of these has fallen from favor, and rheumatology doesn't even rate a mention in the Precision Medicine Initiative.
When it comes to discussing medication risks, a new study shows, rheumatologists and their patients are speaking different languages. The article reveals how doctors may be sending messages they don't intend.
Prior authorizations have begun to spread pandemic-like from high-cost biologics to treatments used routinely in rheumatology. The time burden on rheumatologists is insupportable, contends the author, who says it's time to take action.
Antinuclear antibody testing and DEXA both appear on a new Canadian list of rheumatology tests to avoid and on a similar 2013 list from the American College of Rheumatology. There are interesting differences in the other 3 choices.